Cancer immunotherapy: exploiting neoepitopes

被引：16
|
作者：
Platten, Michael [1 ,2 ,3 ]
Offringa, Rienk [4 ,5 ]
机构：
[1] German Canc Res Ctr, DKTK Clin Cooperat Unit Neuroimmunol & Brain Tumo, Heidelberg, Germany
[2] Univ Heidelberg Hosp, Neurol Clin, Heidelberg, Germany
[3] Natl Ctr Tumor Dis, Heidelberg, Germany
[4] German Canc Res Ctr, Dept Mol Oncol Gastrointestinal Tumors, Heidelberg, Germany
[5] Univ Heidelberg Hosp, Surg Clin, European Pancreas Ctr, Heidelberg, Germany
来源：
CELL RESEARCH | 2015年 / 25卷 / 08期
关键词：
T-CELLS; BLOCKADE; ANTIGENS; MELANOMA;
D O I：
10.1038/cr.2015.66
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
The efficacy of cancer vaccines has long been hampered by insufficient definition of tumor-specific antigens. A recent study by Kreiter et al. published in Nature has provided a blueprint for a patient-tailored approach to develop individualized RNA vaccines.
引用
收藏
页码：887 / 888
页数：2
相关论文
共 50 条
  • [1] Exploiting temporal aspects of cancer immunotherapy
    Zemek, Rachael M.
    Anagnostou, Valsamo
    Pires da Silva, Ines
    Long, Georgina V.
    Lesterhuis, Willem Joost
    NATURE REVIEWS CANCER, 2024, 24 (07) : 480 - 497
  • [2] The double-edged sword of cancer mutations: exploiting neoepitopes for the fight against cancer
    Alvarado-Cruz, Isabel
    Meas, Rithy
    Paluri, Sesha Lakshmi Arathi
    Carufe, Kelly Estelle Wheeler
    Khan, Mohammed
    Sweasy, Joann Balazs
    MUTAGENESIS, 2020, 35 (01) : 69 - 77
  • [3] APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy
    Driscoll, Christopher B.
    Schuelke, Matthew R.
    Kottke, Timothy
    Thompson, Jill M.
    Wongthida, Phonphimon
    Tonne, Jason M.
    Huff, Amanda L.
    Miller, Amber
    Shim, Kevin G.
    Molan, Amy
    Wetmore, Cynthia
    Selby, Peter
    Samson, Adel
    Harrington, Kevin
    Pandha, Hardev
    Melcher, Alan
    Pulido, Jose S.
    Harris, Reuben
    Evgin, Laura
    Vile, Richard G.
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [4] The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy
    Yau, Helen Loo
    Ettayebi, Ilias
    De Carvalho, Daniel D.
    TRENDS IN CELL BIOLOGY, 2019, 29 (01) : 31 - 43
  • [5] Intron retention is a source o neoepitopes in cancer
    Smart, Alicia C.
    Margolis, Claire A.
    Pimentel, Harold
    He, Meng Xiao
    Miao, Diana
    Adeegbe, Dennis
    Fugmann, Tim
    Wong, Kwok-Kin
    Van Ailen, Eliezer M.
    NATURE BIOTECHNOLOGY, 2018, 36 (11) : 1056 - +
  • [6] Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival
    Wood, Mary A.
    Weeder, Benjamin R.
    David, Julianne K.
    Nellore, Abhinav
    Thompson, Reid F.
    GENOME MEDICINE, 2020, 12 (01)
  • [7] Immunotherapy in ovarian cancer
    Odunsi, K.
    ANNALS OF ONCOLOGY, 2017, 28 : 1 - 7
  • [8] Cancer Immunotherapy - The Target is Precisely on The Cancer and Also Not
    Koo, Si Lin
    Wang, Who Whong
    Toh, Han Chong
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2018, 47 (09) : 381 - 387
  • [9] Exploiting the immunomodulatory properties of chemotherapeutic drugs to improve the success of cancer immunotherapy
    Kersten, Kelly
    Salvagno, Camilla
    de Visser, Karin E.
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [10] The Role of Neoantigens in Cancer Immunotherapy
    Zhu, Yueting
    Liu, Jiyan
    FRONTIERS IN ONCOLOGY, 2021, 11
12345